Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicitiesSequential dosing of INDUKINE™ molecules in preclinical model ...
Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback